spec sheet10 rows
1cP-MiPLA is a doubly modified lysergamide combining a cyclopropanecarbonyl group on the indole nitrogen with the N-methyl-N-isopropyl amide substitution that defines MiPLA (lysergic acid methylisopropylamide). It was first formally identified in seized blotter products, and analytical stability studies show that it undergoes N-deacylation to MiPLA, supporting a prodrug relationship analogous to that between 1cP-LSD and LSD, although this deacylation is less pronounced than in the diethylamide series. MiPLA is an LSD-like 5-HT2A receptor agonist generally reported as somewhat milder and more manageable than LSD, so 1cP-MiPLA is expected to yield a comparatively gentle psychedelic profile. Its receptor pharmacology has not been directly measured, and the existing literature is predominantly forensic and analytical.
- LSD-like but often milder
- More manageable headspace
- Classic visual character
- Cyclopropanoyl prodrug of milder MiPLA
- Anxiety possible
- Vasoconstriction
- Insomnia after use
Mechanism
The active molecule works chiefly as an at the receptor, the receptor central to the psychedelic state, with additional serotonergic activity. The 1-cyclopropanoyl group is thought to be cleaved after dosing to release MiPLA, whose N-methyl-N-isopropyl amide is a small tweak of LSD's diethylamide that tends to soften and slightly shorten the effects. Because it is an obscure analog, precise potency and receptor numbers are not well established.
receptor fingerprint
receptoragonist (via MiPLA)
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
This is a little-studied compound; MiPLA is often described as gentler than LSD but is still a genuine psychedelic and potency here is uncertain. Avoid with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
A research chemical whose entire literature is forensic and analytical; the milder MiPLA character is plausible, but nobody has measured its potency, so the dose is guesswork and overshooting is the likely failure. Better characterised lysergamides exist if this family is the goal.
Resources
This entry is here for reference.
Research
- 2017first citedCrystal Structure of an LSD-Bound Human Serotonin Receptor.
- 2026most recentComparative stability assessment of novel LSD analogs in dry blood spots and blood using UHPLC-…
- 1.Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
- 2.A highly sensitive UHPLC-MS/MS method for determining 15 designer LSD analogs in biological samples with application to stability studies.
- 3.Forensic Aspects of Designer LSD Analogs Identification by GC-MS (EI) and UV Spectroscopy.
- 4.Comparative stability assessment of novel LSD analogs in dry blood spots and blood using UHPLC-MS/MS: implications for forensic applications.
- 5.Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
- 6.Crystal Structure of an LSD-Bound Human Serotonin Receptor.
- 7.Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is MiPLA weaker than LSD?
It is commonly reported as somewhat less potent and gentler than LSD; 1cP-MiPLA is thought to deliver that same parent compound.
Is it well characterized?
No; it is an obscure research chemical, so its numbers are only loosely known.
Can it be combined with SSRIs?
Mixing serotonergic drugs can be risky; be cautious with any lysergamide. This is not medical advice.
Adverse effects
- Anxiety possible
- Vasoconstriction
- Insomnia after use
Notes and cautions
- Uncertain potency